Molecular & Translational Drug Discovery

G protein-coupled receptors (GPCRs) are the largest family of receptors and are responsible for regulating a range of physiological functions and pathology. Approximately 40% of marketed drugs target this receptor family. We utilize a variety of platforms, techniques and collaborations in order to progress GPCR discovery projects towards clinical development. Research in this laboratory covers a range of disciplines including structural biology, molecular pharmacology, cellular & native tissue pharmacology and translational biology.

Neuropsychiatry Discovery: The lab has a significant research interest in drug discovery for neuropsychiatric disorders, including projects studying the role of the orphan GPCRs, muscarinic acetylcholine, and serotonin (5-HT) receptors in depression, schizophrenia, cognitive disorders and addiction. This work supports the broader mission of the Neuromedicines Discovery Centre.

Servier Discovery Program: Our collaborative portfolio includes neuro-immune projects at different stages of the preclinical drug discovery process.

For further information, please contact Chris Langmead or Greg Stewart.